-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on GRI Bio, Raises Price Target to $36

Benzinga·12/08/2025 10:25:16
Listen to the news
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and raises the price target from $35 to $36.